

r.g.
\$6-

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

32245/93

(51) International Patent Classification ⁵ : A61F 2/04	A3	(11) International Publication Number: WO 93/10722 (43) International Publication Date: 10 June 1993 (10.06.93)
---	-----------	---

663150

PROPERTY OF ORGANISATION

-1-

FETAL MEMBRANE TUBES FOR
NERVE AND VESSEL GRAFTS

5 Field of the Invention

The present invention is directed to fetal membrane tubes for nerve and vessel grafts.

Background of the Invention

10 Fetal membranes, amnion and chorion, have been selected as our starting material for several reasons. The fetal membranes preferably are human although animal membranes can be used. (1) In one aspect of the invention, we have demonstrated a low immunogenicity of the human amniotic and chorionic conduits in rats which was evidenced when different
15 antigens in their membranes, mainly collagen types I, II, and III fibronectin, and laminin were tested by dot blot and ELISA techniques. (2) Human placentas are available in relatively unlimited quantities and at low cost. (3) For almost 90 years amnion and chorion have been used for a wide variety of
20 medical and surgical indications. (4) They have been shown to be capable of neovascularization. (5) They have also been placed in subcutaneous pockets in human without evidence of acute rejection for as long as 7 weeks. The fetal membranes are of a complex biochemical structure with unique physical
25 characteristics. They can be modified physically by the processing technique later described herein into conduits which are semi-rigid, resilient, and of variable length, diameter and thickness. The biochemical components of the
30 amnion and chorion membranes are mainly collagen types I, II, and III, laminin, fibronectin and other glycoproteins. Laminin has been shown to promote axon extension by

-2-

interacting with axonal glycoproteins that are members of the integrin family of receptors. The immunocytochemical studies we conducted led us to modify our processing technique of the amnion and chorion membranes in order to preserve laminin as a significant component of these conduits, as later described herein.

While human amnion and chorion membranes are preferred, these membranes from other animals, such as bovine membranes, are another aspect of the present invention.

Clinically, it is accepted that the use of a nerve autograft is the method employed to reconstruct a nerve gap. The disadvantages of nerve autografts are shown to be many, i.e. an additional surgical procedure is required, scarring with anesthesia or hyperesthesia at the donor site may be a problem, and there frequently are dimensional limitations of the donor grafts. Although nerve allografts have overcome several disadvantages of the autografts, rejection of the graft remains a major problem and limits its clinical use despite the use of immunosuppressive agents.

The current interest and future directions in nerve research focus on the development of an ideal nerve conduit for clinical use. Several investigators have studied the use of different materials including silicone rubber, PTFE, polyorthoester, polyglactin, mesothelial tubes, muscle basal lamina, and vein grafts as nerve conduits. Each of these materials mentioned has shortcomings and none have proven to provide the ideal environment for the regenerating nerve. An ideal nerve conduit should be readily available, of low cost, easily manufactured, of different sizes, non-immunogenic, microporous, noncollapsible, biodegradable, and of biochemical components that provide a favorable environment for the regenerating axons. As later described herein, we have developed a nerve conduit using human amnion membrane which possess s many of th characteristics of the proposed ideal nerve conduit.

-3-

A number of investigators are currently exploring the use of collagen for nerve conduits. By necessity, this collagen is either allogenic or xenogeneic in origin and, thus, could stimulate an immune response that may inhibit nerve regeneration. Immunological testing of the amniotic and chorionic nerve conduits of the present invention showed a minimal, nonsignificant immune response, thus, avoiding some of the inhibiting factors that could influence the regenerating nerve. Although amniotic and chorionic conduits showed signs of biodegradability and structural reorganization grossly and by electron microscopic examination, local inflammatory cells infiltration was slight, being limited to the area surrounding the conduit wall, and it did not produce changes similar to those of chronic nerve compression. This latter development is a major problem encountered with the use of silicone rubber conduits for nerve regeneration.

Functional and morphological assessment of nerve regeneration using amniotic and chorionic conduits proved its superiority to nerve autografts and silicone tubes.

Also, there is a need for blood vessels which can be connected to their proximal and distal ends when blood vessels are severed such as when thrombosis occurs and blood vessel segments are removed. In bypass operations, veins stripping in the legs for these purposes can be avoided and similarly in subsequent bypass operations as the patient does not have adequate vein to take the place of the thrombosed arteries which are removed. Also, vein graft wall collapse and obliteration of its lumen added to the donor's site morbidity are significant problems which limit their use. Vascular conduits commonly used are vein grafts harvested from the patient's legs or arms. The donor site morbidity and the unpredictable patency of vein grafts for coronary bypass and peripheral vascular interposition bypass grafts are well known. Several vascular conduits have been tried and in common use including preserved bovine vein grafts, dacron prosthetic grafts, teflon, and umbilical artery grafts. The

-4-

high incidence of the thrombosis and infection of these grafts is also a problem. To construct an ideal vascular graft, the graft should be non-thrombogenic, easily accessible, of variable diameters and lengths, extensible, and flexible.

5 Amniotic and chorionic collagen tubes or conduits according to the present invention are non-immunogenic and can be constructed into tubes of variable lengths and diameters readily and easily. The amniotic and chorionic tubes of the present invention are well suited for use as nerve grafts or
10 as bypass conduits for coronary bypass or vascular bypass surgery.

Summary of the Invention

The present invention is directed to providing nerve and vessel tubes or conduits for grafting to bridge gaps in
15 nerves and vessels. The physical characteristics of the Types I, II, III collagen derived from the amnion and chorion placentas in membrane form have been modified and the tubes constructed so that they are maintained patent and flexible so blood flows through their lumen and their walls can withstand
20 the interstitial pressure, and in which the fetal side or shiny side of the membrane is the inward side, which in the case of nerve grafts promotes axon growth.

^{a preferred embodiment}
In ~~one aspect~~ of the invention, to provide such a graft, amnion and chorion is obtained from fresh placentas,
25 preferably human, the amnion and chorion layers are separated from the placenta and each other, cellular monolayer material overlying the basal lamina on the fetal side of the membrane is removed, such as by exposure to trypsin or pepsin, the amnion and chorion is rinsed repeatedly with phosphate buffer
30 solution or distilled water until clean, the amnion or chorion is then cross-linked either by exposure to gamma radiation or chemical cross-linking such as with glutaraldehyde, which sterilizes the tissue, provides protection against viral disease transmission, strengthens and permits remodeling the
35 material from sheet to conduit form. The amnion and chorion sheets are then wrapped in layers so that the fetal surface,

ALIA

which is shiny, is directed toward the inner surface of the finished tube. The number of wraps will depend upon the length and diameter of the tube. The tubes are then dried and placed in bottles which are sealed, labeled and, if desired, exposed to 2.5M rads of gamma radiation to again sterilize and further cross-link the conduit collagen. If desired, the layers can be glued together by a suitable glue, such as a fibrin glue, to prevent delaminating, particularly in larger conduits, such as used for vascular grafts.

The tubes or conduits can then be stored, for example at -20°C , until used.

For nerve grafts, nerve promoting factors can be used within the amnion and chorion tubes at the time of implantation, for example particles of basal lamina, fibronectin, collagen extract, nerve growth factors and other related growth factors.

Accordingly, it is an object of the present invention to provide a tubular graft for joining proximal and distal stumps or ends of a severed peripheral nerve or proximal and distal ends of a vessel which avoids the foregoing disadvantages of the prior art and has the advantages mentioned above.

According to the present invention there is provided a graft for bridging a gap between proximal and distal ends of at least one of a severed nerve and proximal and distal ends of a vessel comprising,

a cylindrical wall formed of at least one layer of a sheet of sterilized, cross-linked amnion membrane from a human placenta having a fetal side and free of epithelial material, the amnion membrane composed of collagen types I and III, laminin, fibronectin and other glycoproteins,

the fetal side directed inwardly,

the cylindrical wall having sufficient layers to maintain said wall patent when in place,

the cylindrical wall having a length sufficient to bridge the gap between the proximal and distal ends, and

having a diameter at least equal to connective tissue of the proximal and distal ends.

5a

According to another embodiment of the present invention there is provided a method for restoring nerve function of a severed nerve comprising,

5 joining proximal and distal stumps of the severed nerve by attaching to said stumps a graft, said graft comprising a hollow cylindrical wall formed of at least one layer of a sheet of sterilized, cross-linked amnion membrane from human placenta free of epithelial material comprised of collagen types I and III, laminin, fibronectin and other glycoproteins, said amnion membrane having a fetal side directed inwardly, and having sufficient layers to maintain the cylindrical wall patent in place.

10 According to a further embodiment of the present invention there is provided a method of replacing a blood vessel comprising,

15 joining proximal and distal ends of the blood vessel by attaching to said ends a graft, said graft comprising a hollow cylindrical wall formed of at least one layer of a sheet of sterilized, cross-linked amnion membrane from human placenta free of epithelial material comprised of collagen types I and III, laminin, fibronectin and other glycoproteins, said amnion membrane having a fetal side directed inwardly, and having sufficient layers to maintain the cylindrical wall patent in place.

-6-

~~A further object of the present invention is to~~
provide such a graft in which the layers of amnion and/or chorion membranes are glued together effective to prevent delamination of the layers.

5 It is still a further object of the present invention to provide such a cylindrical graft in which its wall permits flow of interstitial fluid through it to provide early nourishment for the graft, and in the case of nerve grafts, to provide nourishment for growth of Schwann cells.

10 It is a still further object of the present invention to provide such a cylindrical graft as a research model for inclusion of material for medication study of nerve regeneration in the field of neurology.

15 It is a further object of the present invention to provide a nerve graft comprised of an amniotic and/or chorionic tube containing related growth factors.

It is a further object of the present invention to provide a nerve graft comprised of an amniotic and/or chorionic tube containing basal lamina particles.

20 It is a further object of the present invention to provide such a graft which can be made in relatively long lengths, which will not kink, will retain its shape and in which the passageway remains patent or open.

Other and further objects, features and advantages
25 of the invention appear throughout.

Description of Preferred Embodiments

A. Amnion Harvesting and Preparation

In this aspect of the invention, amnion is obtained from fresh human placentas. The placentas are from hospital
30 labor and delivery within 24 hours of parturition. Placentas obtained only from mothers who have been screened for AIDS and hepatitis virus and who are not members of the high risk groups such as IV drug abusers are used. Care is taken to avoid skin contact with blood and tissue and to minimize
35 contamination of the work areas with these materials.

STRALIA

-7-

The amnion layer is separated from the placenta, such as by finger dissection. The largest possible pieces of amnion which are of uniform thickness are selected from all the amnion harvested. The selected pieces of membrane are
5 thoroughly washed, preferably with phosphate buffered saline, or distilled water to remove all the blood and debris. Then the membranes are further washed until they are white and transparent.

The cellular monolayer overlying the basal lamina on
10 the fetal side of the membrane is removed, such as by exposure to trypsin. Membranes are immersed for two hours at room temperature in 1:1 solution of distilled water and trypsin. The trypsin used preferably is from the procine pancreas at a 25% concentration without calcium or magnesium. Following
15 treatment with trypsin, the amnion is rinsed repeatedly, preferably with phosphate buffered saline, or with distilled water until clean, white membranes with no trace of pink trypsin are obtained.

Rinsed amnion sheets are bottled in distilled water
20 and exposed to 500,000 rads of gamma radiation. Irradiating the amnion cross-links the collagen, sterilizes the tissue, provides animal protection against viral disease transmission and subsequent remodeling of the material from sheet to conduit or tubular form. The bottles are then stored in a
25 freezer at -80°C. If desired, the amnion sheets may be cross-linked chemically such as with glutaraldehyde.

B. Conduit Manufacturing

Amnion is removed from frozen storage and then thawed for 3 to 4 hours at room temperature. The amnion
30 sheets are examined under the operating microscope for defects and determination of the fetal or shiny side of the membrane. By using a rolling machine, sheets of the amnion wide enough for a desired conduit length and diameter are carefully collected. The amnion sheets are oriented so that the fetal
35 surface, which is shiny, would be directed towards the inner surface of the finished tube.

-8-

Preferably, wrapping of the amnion sheets in layers is effected by using a highly polished stainless steel stent of the appropriate diameter, although the amnion sheets can be wrapped in any desired manner.

5 The number of wraps or layers of the amnion sheets necessary to maintain the amnion cylinder's shape, avoid kinking and to keep it patent or open depend upon the length and diameter of the tube or cylinder. For example, conduits of 1.6-1.8 inches in diameter require approximately 10 wraps
10 of amnion and 15 wraps are satisfactory for a diameter of 2.5. The conduits can be of any desired length. The tubes which are on the stents are then dried in 40-60°C oven for about 30 minutes. Drying allows the tubes to be removed from the stents easily. If desired, to prevent delamination, a suitable
15 adhesive or glue, such as fibrin glue, can be used to glue the layers or wraps of amnion sheets together. The tubes are then placed in bottles which are sealed, labeled, and exposed to 2,000,000 rads of gamma radiation to again sterilize and further cross-link the conduits collagen. After that, the
20 conduits are stored in -20°C until used.

Example 1

In this example, the basement membrane integrity and laminin content of human amnion before, and after, the construction of the conduits were evaluated by
25 immunocytochemical methods. Human amniotic conduits according to the invention have low immunogenicity which was evidenced when different antigens in the amnion membrane, mainly collagen type 1, fibronectin, and laminin were tested by dot blot and ELISA techniques. For almost 90 years amnion
30 has been used for a wide variety of medical and surgical indications and has been shown to be capable of neovascularization. It has also been placed in subcutaneous pockets in human without evidence of acute rejection for as long as 7 weeks.

35 The fetal membranes are of a complex biochemical structure with unique physical characteristics. They are

RAIA
K

-9-

modified physically in the present invention by the process technique described herein into conduits which are semi-rigid, resilient, and of variable length, diameter and thickness. The biochemical components of the amnion membrane are mainly collagen type I and type III, laminin, fibronectin and other glycoproteins. Laminin has been shown to promote axon extension by interacting with axonal glycoproteins that are members of the integrin family of receptors. The methods of processing the amnion membrane of the present invention preserve laminin as a significant component of these components. The present method of using gamma irradiation has several advantages. It has been shown that all bacteria, fungi, and viruses (including AIDS) are destroyed at .20 M rads. Preferably, a dose of 2.5 M rads is used in order to ensure complete sterility of the final material. This dose also increases amniotic collagen cross-linking which strengthens and thus enables the manufacture of the amniotic conduits in a semi-rigid form while retaining some resiliency to maintain patency after implantation. As indicated previously, however, chemical cross-linking by known methods, such as exposure to glutaraldehyde, is effective and satisfactory.

By immunological testing, the amniotic nerve conduit showed a minimal, nonsignificant immune response, thus, avoiding some of the inhibitory factors that could influence the regenerating nerve. Although amniotic conduits showed signs of biodegradability and structural reorganization grossly and by electron microscopic examination, local inflammatory cells infiltration was slight, being limited to the area surrounding the conduit wall, and it did not produce changes of chronic nerve compression. This latter development is a major problem encountered with the use of silicone rubber conduits for nerve regeneration recently presented for clinical use.

Long-term studies of the amniotic conduits showed major structural changes as evidenced by Schwann-like cells

-10-

infiltration through the layers of conduit and collagen reorganization, indicating a phenomenon of biodegradability and reorganization, a characteristic unique to the amniotic conduit.

5 As previously mentioned, the amniotic tube of the present invention can be used as a carrier for many materials that promote nerve regeneration, such as ^{basal} lamina, fibronectin, collagen extract, nerve growth factors, and other related factors. Collagen extract is collagen extracted from human
10 fetal membranes such as described in U.S. Patent No. 5,002,071. For example, basal lamina can be used as freeze dried ground, polarized, or preserved in any preservative solution within the amnion tube at the time of implantation.

Example 2

15 In this example, nerve regeneration through a conduit according to the present invention was compared morphologically and functionally with autographs and other types of nerve tubes in an experimental animal model.

Eleven cats were divided into five groups to assess
20 nerve regeneration through a 4 cm gap of the tibial nerve.

Group 1 (3 animals) amnion tube.

Group 2 (3 animals) amnion tube and basal lamina as a neurotrophic factor extracted form muscle.

Group 3 (3 animals) nerve autograft.

25 Group 4 (1 animal) sham operation as a control.

Group 5 (1 animal) no repair.

The animals were followed for six months when they were harvested, and the nerve segments were studied morphologically and histologically.

30 The cats were anesthetized using Demerol and phenobarbital intramuscular and a mixture of Halothane and No₂ by inhalation. The tibial nerve was exposed, and a 4 cm s gment was excised and repaired as following:

35 In group 1 (amnion) an amnion tube was sutured to the distal and proximal stumps ensuring a gap of 4 cm. Two stitches wer placed 180° apart on each side and went through

-11-

the whole thickness of the tube containing only the epineurium of the nerve stump.

In group 2 (amnion tube - basal lamina) - same as above, a 4 cm segment of the nerve was excised, and the gap was bridged by an amniotic tube filled with basal lamina.

In group 3 (nerve autograft) a 4 cm segment was excised, then reattached using epineural technique.

In group 4 (sham) the tibial nerve was explored and left undisturbed.

In group 5 (no repair) a 4 cm segment of the tibial nerve was excised, and no repair was ensured by suturing the nerve stumps to the underlying muscle.

The animals were followed for six months, and no functional improvement was noticed in any of the experimental groups excluding the sham.

At six months the cats were sacrificed and morphological and histological studies were performed. The results recommend amnion basal lamina as a strong candidate for nerve regeneration and show that the addition of muscle basal lamina to the amniotic collagen tube enhances nerve regeneration.

In axonal diameter histograms the amnion basal lamina group showed a distribution comparable to the sham with even larger axons and a considerable percentage of the axons (9%) fell in the range of from 1.5 to 2.25 microns. In the case of nerve autograft, the histogram was comparable with the sham but with more percentage of axons (37%) falling in the range from 0.5 to 0.75 microns. In the amnion tube group the axonal diameters ranged between 0.1 to 1 micron with most of the axons (58%) falling in the range 0.25 to 0.5 microns. The axonal diameter histograms showed that basal lamina helped in rendering larger axons and provided to be the closest to the normal.

The conclusions from this example are that human amniotic conduits are strong substitutes for nerve grafting and muscle basal lamina proved to be a good neurotrophic

-12-

material when added to the amniotic collagen tube. Amnion conduits filled with basal lamina are superior to nerve autografts. Human amniotic collagen tubes are good conduits for nerve regeneration and can be used to house any neurotrophic material.

Example 3

In this example, human chorion was substituted for human amnion. The chorion membrane was separated from the amnion membrane and was then harvested and treated the same as in paragraph A, and conduits formed the same as in paragraph B has properties similar to those set forth in Examples 1 and 2, and is satisfactory for both nerve growth and vascular tubes. The step of using trypsin or pepsin may be omitted if the chorion is separated from the amnion.

Example 4

In this example, collagen Types I, II, and III, and combinations thereof derived from bovine amniotic and chorionic membranes were substituted for human membranes and prepared and formed into conduits or tubes as described above and provide similar and satisfactory results for both nerve growth and vascular tubes as set forth above for the human membranes.

The methods of the invention comprise joining the proximal and distal stumps or ends of a severed nerve or proximal and distal ends of a vessel with a tube comprised of at least one layer of sterilized cross-linked membrane free of cellular or epithelial material comprising Types I, II, III collagen or mixtures thereof, laminin, fibronectin and other glycoproteins, having its fetal side directed inwardly. The membrane is sterilized and cross-linked by irradiation or chemically and has sufficient layers to maintain them patent in place. The tube has a length at least equal to the distance between the proximal and distal stumps or ends, and has a diameter at least equal and preferably slightly larger than connective tissue of the proximal and distal stumps or ends. For nerve grafts the tube can contain nerve growth

-13-

factors, such as basal lamina, fibronectin or collagen extract or combinations of them, as previously mentioned. The tube is sutured or otherwise secured to the connective tissue adjacent the nerve stumps or vessel ends.

5 The grafts are storable for extended periods of time providing a ready available source of graft material. The grafts can be formed of any required diameter and length, and the layers of the graft can be glued together to prevent delamination of the layers in use.

0 Accordingly, grafts for bridging a gap between proximal and distal ends of a severed nerve or of a vessel comprising a cylinder having a wall formed of at least one layer of sterilized cross-linked membrane derived from Types I, II, III collagen or combinations thereof from placenta are
5 suitable and satisfactory.

 Accordingly, the present invention is well suited and adapted to attain the objects and ends and has the features and advantages mentioned as well as others inherent therein.

0 While presently preferred embodiments of the invention have been given for the purposes of disclosures, changes and modifications can be made within the spirit of the invention as defined by the scope of the appended claims.

What is claimed is:

The claims according to the invention are as follows:

1. A graft for bridging a gap between proximal and distal ends of at least one of a severed nerve and proximal and distal ends of a vessel comprising,
 - 5 a cylindrical wall formed of at least one layer of a sheet of sterilized, cross-linked amnion membrane from a human placenta having a fetal side and free of epithelial material, the amnion membrane composed of collagen types I and III, laminin, fibronectin and other glycoproteins,
 - the fetal side directed inwardly,
 - 10 the cylindrical wall having sufficient layers to maintain said wall patent when in place,
 - the cylindrical wall having a length sufficient to bridge the gap between the proximal and distal ends, and
 - having a diameter at least equal to connective tissue of the proximal and distal ends.
2. A graft as claimed in claim 1 wherein,
 - said wall comprises at least two layers of said membrane in sheet form glued together effective to prevent delamination of the layers in use.
3. A graft as claimed in claim 1 or claim 2 where,
 - the graft permits flow of interstitial fluid through its cylindrical wall.
4. A graft as claimed in any one of claims 1 to 3 where,
 - the graft is a nerve graft and contains at least one nerve growth factor.
5. A graft as claimed in any one of claims 1 to 4 where,
 - the graft is a nerve graft and contains basal lamina, fibronectin, amniotic collagen extract or combinations thereof.

5 6. A method for restoring nerve function of a severed nerve comprising,
joining proximal and distal stumps of the severed nerve by attaching
to said stumps a graft, said graft comprising a hollow cylindrical wall
formed of at least one layer of a sheet of sterilized, cross-linked amnion
membrane from human placenta free of epithelial material comprised of
collagen types I and III, laminin, fibronectin and other glycoproteins, said
amnion membrane having a fetal side directed inwardly, and having
sufficient layers to maintain the cylindrical wall patent in place.

10 7. A method for restoring nerve function of a severed nerve as claimed in
claim 6, further including,

providing at least one nerve growth factor in the hollow cylindrical
wall.

15 8. A method for restoring nerve function of a severed nerve as claimed in
claim 6 or claim 7, further including,

providing basal lamina in the hollow cylindrical wall.

20 9. A method of replacing a blood vessel comprising,

joining proximal and distal ends of the blood vessel by attaching to
said ends a graft, said graft comprising a hollow cylindrical wall formed of
at least one layer of a sheet of sterilized, cross-linked amnion membrane
from human placenta free of epithelial material comprised of collagen types
I and III, laminin, fibronectin and other glycoproteins, said amnion
membrane having a fetal side directed inwardly, and having sufficient
layers to maintain the cylindrical wall patent in place.

25 30 10. A method as claimed in any one of claims 6 to 9, further including,

providing at least two of the layers of the sheet of sterilized, cross-
linked amnion membrane glued together effective to prevent delamination
of the layers in use.



11. A method as claimed in any one of claims 6 to 10, further including, providing the graft in a form which permits flow of interstitial fluid through the cylindrical wall.

5 12. A method as claimed in claim 7, further including, having the nerve growth factor selected from the group consisting of basal lamina, fibronectin, amniotic collagen extract, and combinations thereof.

10 13. A graft according to claim 1 substantially as hereinbefore described with reference to any one of the Examples.

14. A method according to claim 6 or claim 9 substantially as hereinbefore described with reference to any one of the Examples.

15 DATED this 28th day of July, 1995.


RESEARCH DEVELOPMENT FOUNDATION
By Their Patent Attorneys:
CALLINAN LAWRIE



INTERNATIONAL SEARCH REPORT

PCT/US92/10165

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61P 2/04

US CL : 623/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 623/901, 1, 9, 66, 11; 606/153, 152, 154

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Amnion, Amniotic or Placenta

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US, A, 4,120,649 (Schechter) 17 October 1978, See abstract.	1-10
X Y	US, A, 4,894,063 (Nasef) 16 January 1990, See column 4, lines 34-52.	1-10
X Y	US, A, 5,026,381 (Li) 25 June 1991, See column 4, lines 68 and column 9, lines 1-32.	1-10
A	US, A, 5,019,087 (Nichols) 28 May 1991, See abstract.	1-10

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

•	Special categories of cited documents:	• T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
• A	document defining the general state of the art which is not considered to be part of particular relevance	• X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
• E	earlier document published on or after the international filing date	• Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
• L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	• &	document member of the same patent family
• O	document referring to an oral disclosure, use, exhibition or other means		
• P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

22 APRIL 1993

Date of mailing of the international search report

13 MAY 1993

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

TNDINH NGUYEN

Telephone No. (703) 308-0858

 NGUYEN NGOC HO
 INTERNATIONAL DIVISION